BPBrian Porter

Brian Porter

*This is an algorithmically generated author record based on publicly available information.

Brian Porter has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison

    by Walter P. Maksymowych, Vibeke Strand, Peter Nash, Yusuf Yazici, Howard Thom, Matthias Hunger, Chrysostomos Kalyvas, Kunal K. Gandhi, Brian Porter, Steffen M. Jugl

    Objective: Matching-adjusted indirect comparison was used to assess the comparative effectiveness of secukinumab 150 mg and adalimumab 40 mg in biologic-naïve patients with ankylosing spondylitis (AS) for up to 1 year. Methods: Pooled individual patient data from the secukinumab arms of MEASURE 1 (NCT01358175) and MEASURE 2 (NCT01649375) trials (n=197) were matched against the ATLAS (NCT00085644) adalimumab population (n=208). Logistic regression analysis was used to determined weights to match for age, sex, Bath AS Functional Index, C-reactive protein levels, and previous tumor necrosis factor inhibitor therapy. Recalculated Assessment of SpondyloArthritis International Society (ASAS) 20 and 40 responses at weeks 8, 12, 16, 24, and 52 from MEASURE 1/2 (effective sample size=120) were compared with those of ATLAS. Anchored (placebo-adjusted) comparisons were possible until week 12, and unanchored (non-placebo- adjusted) comparisons were necessary thereafter. Results: For placebo-anchored ASAS 20 and 40 comparisons up to week 12, there were no differences between secukinumab and adalimumab. For unanchored comparisons at week 16, ASAS 20 was higher for secukinumab [odds ratio 1.60 (95% confidence interval, 1.01-2.54); p=0.047]; at week 24, ASAS 20 and 40 were higher for secukinumab [1.76 (1.11-2.79); p=0.017 and 1.79 (1.14-2.82); p=0.012, respectively]; and at week 52, ASAS 40 was higher for secukinumab [1.54 (1.06-2.23); p=0.023] than for adalimumab. Conclusion: There were no differences observed in placebo-adjusted ASAS 20 and 40 responses up to 12 weeks between secukinumab- and adalimumab-treated patients with ankylosing spondylitis. After week 12, secukinumab demonstrated signs of greater improvement in non-placebo-adjusted ASAS 20 and 40 responses than adalimumab. Cite this article as: Maksymowych WP, Strand V, Nash P, Yazici Y, Thom H, Hunger M, et al. Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison. Eur J Rheumatol 2018; 5: 216-23.


  • 176 Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through three years: long-term results of two randomised double-blind placebo-controlled phase III studies

    by Helena Marzo-Ortega, Tore K Kvien, Atul A Deodhar, Laure Gossec, Philip G Conaghan, Vibeke Strand, Mikkel Østergaard, Nicole Williams, Brian Porter, Kunal Gandi, et al.

    Background: Fatigue is common in patients with ankylosing spondylitis (AS) and negatively impacts social functioning and quality of life. We assessed the long-term effects of secukinumab on fatigue in TNF inhibitor (TNFi)-naive and TNFi inadequate responder/intolerant (TNFi-IR) AS patients in MEASURE 1 and MEASURE 2.


  • Open Access

    107. LONG-TERM EFFICACY OF SECUKINUMAB CONDITIONAL ON RESPONSE STATUS AT WEEK 12: ANALYSIS IN TUMOUR NECROSIS FACTOR α INHIBITOR–NAÏVE AND TUMOUR NECROSIS FACTOR α INHIBITOR INADEQUATE RESPONDER PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS

    by Paul Emery, Anna Halliday, Steffen Jugl, Soniya Mokashi, Brian Porter, Ruvie Martin, Bintu Sherif, Nicole Williams, Helena Marzo-Ortega

    Background: Ankylosing spondylitis (AS) is a chronic arthritic disease associated with pain and functional deterioration. Patients with active AS and an inadequate response to conventional therapy can be treated with several licensed biologic agents including tumour necrosis factor α (TNF-α) inhibitors and secukinumab, a first-in-class, fully human interleukin-17A inhibitor. However, treatment guidelines highlight the importance of assessing response to biologics after 12 weeks and only continuing treatment if there is clear evidence of response. Secukinumab has been demonstrated to significantly improve the signs and symptoms of AS in two randomized controlled trials, MEASURE 1 and MEASURE 2. This analysis aimed to assess the importance of response status at 12 weeks as an indicator of longer-term outcomes with secukinumab 150 mg in TNF-α inhibitor–naïve and TNF-α inhibitor inadequate responder (TNF-α inhibitor-IR; primary or secondary treatment failure, contraindications or intolerance).